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ABSTRACT
Sex Differences in Nicotine-conditioned Hyperactivity in a Model of Dopamine D2 Receptor
Priming: Roles of Dopamine D2 and D3 Receptor Subtypes
by
Ashley Brianna Sheppard
The aim of this investigation was to determine the effect of a nicotine-conditioned context on
locomotor hyperactivity in an animal model of D2-priming, and whether conditioned
hyperactivity could be blocked by the D2 antagonist eticlopride or the D3 antagonist nafadotride.
D2-primed male rats showed enhanced nicotine sensitization as evidenced by statistically
significant differences in horizontal activity. D2-primed female rats administered nicotine
demonstrated an increased hypoactive response after initial sensitization and increased
stereotypy. Eticlopride and nafadotride blocked sensitization to nicotine in both D2-primed and
non D2-primed males and females. Eticlopride blocked conditioned hyperactivity in females but
not in males. D2-primed female rats administered nicotine demonstrated significantly higher
conditioned-hyperactivity as compared to non D2-primed females and controls, and this increase
was more effectively blocked by nafadotride as compared to eticlopride. These results suggest
differential roles of the dopamine D2 and D3 receptors in both adolescent nicotine sensitization
and conditioned activating effects of nicotine.
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CHAPTER 1
INTRODUCTION
Smoking is a convenient and legal form of drug self-administration that often begins in
adolescence. Addiction to nicotine, the psychomotor stimulant drug found in cigarettes, often
results (Benowitz, 1988; Faraday, Elliott, Phillips, & Grunberg, 2003; Jarvis, 2004). Nicotine has
positive reinforcing effects that typically become associated with environmental and contextual
cues (Bevins & Palmatier, 2003; Bevins, Eurek, & Besheer, 2004; Jarvis; Lazev, Herzog, &
Brandon, 1999). After many pairings of smoking with a particular environment or within a
specific context, the context in which the individual smokes appears to elicit strong cigarette
cravings followed by smoking behavior (Bevins & Palmatier; Brandon, Piasecki, Quinn, &
Baker as cited in Lazev et al., 1999; Jarvis). A rise in smoking-related health problems,
evidenced by lung cancer surpassing breast cancer as the leading type of cancer in women in the
United States, suggests that women in general are more sensitive to the effects of nicotine, have
greater difficulty quitting, and use tobacco more frequently than men (Grunberg, Winders, &
Wewers, 1991; Kandel, Warner, & Kessler as cited in Harrod et al., 2004; Waldron, 1991).
The schizophrenic population in particular exhibits especially high rates of smoking
which is nearly three times that of the general population (Kelly & McCreadle, 1999). According
to the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV) (American Psychiatric Association, 2000), schizophrenia is a psychotic disorder in
which patients experience symptoms such as delusions, hallucinations, disorganized speech,
catatonic motor behavior, and negative affect. The disorder usually has an age of onset between
the late teens and mid-30s (American Psychiatric Association). Individuals suffering from
schizophrenia exhibit impairments in many cognitive functions such as memory, attention, and
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psychomotor abilities (American Psychiatric Association). The high incidence of smoking
among these patients raises the possibility of an underlying neurochemical mechanism involving
nicotine in which the midbrain dopaminergic system, also referred to as the mesocorticolimbic
pathway, has been implicated (Dalack, Healy, & Meador-Woodruff, 1998).
The Dopamine System
Dopamine, a catecholamine neurotransmitter that contains an amine group and a catechol
ring, is synthesized from the amino acid tyrosine obtained from dietary protein (Kalat, 2004).
Dopamine is a modulatory neurotransmitter that acts via two families of G-protein-coupled
receptors that are divided into these two families based on similar pharmacological profiles
towards dopamine agonists and antagonists (Cooper, Bloom, & Roth as cited in Kostrzewa,
1995; Missale, Nash, Robinson, Jaber, & Caron, 1998). The dopamine D1-like receptor family
consists of the D1 and D5 receptor types and the dopamine D2 -like receptor family consists of
D2, D3 and D4 receptor types (Kostrzewa, 1995). Overactivity of the dopamine system has been
implicated as playing a primary role in schizophrenia, obsessive-compulsive disorder (OCD),
and bipolar disorder (Kostrzewa). Also, genetic polymorphisms of the D2 and D4 receptors have
been reported in attention-deficit hyperactivity disorder (ADHD) (Bobb, Castellanos, Addington,
& Rapoport, 2005).
Behavioral changes resulting from the pharmacological induction of increases in
dopaminergic activity in laboratory animals have been shown to produce symptoms similar to
those observed in schizophrenic patients (Braff & Geyer, 1990). For example, studies from our
laboratory have shown deficits in prepulse inhibition (PPI), a deficit commonly seen in
schizophrenia (Adler, Freedman, Ross, Olincy, & Walso, 1998). This effect is hypothesized to
result from increased dopamine D2 receptor supersensitivity as a consequence of neonatal
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quinpirole treatment (Smith, Perna, & Brown, unpublished data). Interestingly, animal studies by
Brown et al. (Brown & Kolb, 2001; Brown, Thompson, Thompson, Thacker, Ward, et al., 2004)
have also shown that adulthood nicotine treatment can improve or alleviate cognitive deficits
produced by neonatal quinpirole treatment. This suggests that schizophrenics may self-medicate
through smoking in an attempt to assuage cognitive deficiencies produced by overactive
dopamine function inherent to the disorder, although the mechanism through which nicotine
works has yet to be delineated (Kumari & Postma, 2005).
It has also been hypothesized that gliosis leading to a decrease in prefrontal dopamine
activity subsequently results in an increase in dopamine D2 receptor sensitivity and
mesocorticolimbic dopamine activity (Angelucci, Mathe, & Aloe, 2004; Davis, Kahn, Ko, &
Davidson, 1991). Mesocorticolimbic dopamine neuron hyperactivity, coinciding with prefrontal
dopamine hypoactivity, has been associated with cognitive deficits observed in schizophrenia
(Davis et al.; Elvevag & Goldberg, 2000; Mackay et al., 1982). Additionally, increases in
dopaminergic activity have been shown to depress cholinergic functioning, and cholinergic
function has been shown to play a major role in cognition (Elvevag & Goldberg). Studies from
our laboratory (Brown, Thompson, Thompson, Thacker, Ward, et al., 2004; Brown, Perna,
Schaffer, & Williams, 2006) as well as Day and Fibiger (1992) have shown that activation of
dopamine D2 receptors depresses acetylcholine function in the hippocampus and produces
cognitive impairment. Thus, it appears that increases in dopaminergic function can result in
changes that alter other neurotransmitter systems with behavioral consequences.
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Rodent Models of Schizophrenia
Rationale for Use of Animal Models
Animal models are valuable tools for studying aspects of diseases. Although there are
limitations, such as the inability to study the long-term progression of a disease, animal models
can be used as a means to elucidate underlying mechanisms and develop effective treatments for
neurological disorders (Woodruff & Baisden, 1994). Another important aspect of animal models
is that although it may be difficult to completely replicate a disorder in an animal, modeling even
one aspect of that disorder can be very useful in discovering treatments. For example,
Alzheimer's disease results in neurodegeneration of all neurotransmitter systems in the brain;
however, drug treatments designed to enhance cholinergic activity were discovered as the result,
at least in part, on animal models of cognitive dysfunction (Yamada & Nabeshima, 2000).
Relevant to this proposal, several rodent models of schizophrenia that used mesolimbic
dopamine hyperactivity as the neural basis of the disease have proven useful in understanding
behavioral and biochemical aspects of the disorder.
Past Models of Schizophrenia: Dopamine Hyperactivity
Several past rodent models of schizophrenia have used acute administration of drugs such
as apomorphine (Lacroix, Broersen, Feldon, & Weiner, 2000), amphetamine (Kokkinidis &
Anisman, 1980), methamphetamine and cocaine (Yamamoto, 1997) that stimulate the dopamine
system. A recently developed model of schizophrenia in which rats were administered
amphetamine i.p. 3 days per week for 5 consecutive weeks has also been shown to create
dopamine receptor supersensitivity as evidenced by amphetamine-induced locomotor activity
and disruption in sensorimotor gating in animals tested using the PPI paradigm (Tenn, Fletcher,
& Kapur, 2003; Tenn, Kapur, & Fletcher, 2005). Additionally, Lacroix et al. (2000) infused the
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indirect dopaminergic receptor agonist apomorphine into the prefrontal cortex which caused a
disruption in prepulse inhibition, a behavioral manifestation of schizophrenia. Although these
models have been beneficial in studying schizophrenia, acute administration of dopaminergic
agonists does not represent the long-term dopamine dysfunction seen in schizophrenic patients.
Other models have used acute administration of phencyclidine (PCP), an NMDA receptor
antagonist, to mimic NMDA receptor hypofunction that is known to occur in schizophrenia
(Heresco-Levy, Silipo, & Javitt, 1996; Millan, 2002, 2005). Noncompetitive blockade of NMDA
receptors using PCP produces both positive and negative symptoms of schizophrenia in normal
subjects (Heresco-Levy et al.). Studies using this model have shown prepulse inhibition deficits
and social withdrawal consistent with schizophrenia (Sams-Dodd, 1997). Additional studies have
shown alleviation of both positive and negative symptoms of schizophrenia using NMDA
agonists such as glycine and D-serine, suggesting NMDA receptors as targets for potential
therapies (Heresco-Levy et al.).
Lipska and Weinberger (2002) have developed a rodent model of schizophrenia through
ablation of the ventral hippocampus in 7-day-old rats. The rationale for this model is based on
known hippocampal neuropathology present in schizophrenia including decreased hippocampal
volume and increased size of the lateral ventricles (Harrison & Eastwood, 2001). Findings from
this model have shown reductions of dopamine transporter (DAT) mRNA in the VTA and
substantia nigra in adult rats (Lipska, Lerman, Khaing, & Weinberger, 2003) as well as several
behavioral deficits seen in schizophrenia including increased locomotor activity and cognitive
impairments (Chambers, Moore, McEvoy, & Levin, 1996). This particular model is challenging
due to unavoidable damage to cortical and some subcortical areas as a result of lesioning the
hippocampus at the early age at which the procedure must be performed. Also, changes in

13

hippocampal synaptic connectivity, but not cell death, have been observed in schizophrenic
patients postmortem, creating another weakness for this particular model (Harrison &
Eastwood).
Neonatal Quinpirole Model: A New Model of Schizophrenia
Quinpirole, a dopamine D2/D3 receptor agonist, administered to rats during the neonatal
period has been shown to produce long-term dopamine D2 receptor supersensitivity, also known
as 'D2 receptor priming'(Kostrzewa, 1995; Kostrzewa & Brus, 1991; Kostrzewa, Hamdi, &
Kostrzewa, 1990). Priming of the D2 receptor refers to increased physiological, biochemical, or
behavioral responses of dopamine D2 receptors to dopamine agonists and is thought to account
for altered drug-induced behavioral responses in several neurological disorders including
schizophrenia, bipolar disorder, and attention-deficit hyperactivity disorder (ADHD) (Bobb,
Castellanos, Addington, & Rapoport, 2005; Kostrzewa; Rosa-Neto et al., 2005; Versiani, 2006).
Dopamine D2 receptor priming has been shown to alter overall brain function through influences
on other neurotransmitter systems, including the acetylcholinergic system (Brown et al., 2004;
Brown, Perna, Schaefer, & Williams, 2006).
Similarities have been observed between the neonatal quinpirole model of schizophrenia
and data from the human schizophrenia literature. For example, amphetamine administration to
adult rats neonatally treated with quinpirole produce a robust increase in dopamine release in the
striatum (Nowak, Brus, & Kostrzewa, 2001). Studies using magnetic resonance imaging (MRI)
and positron emission tomography (SPECT) imaging have shown that amphetamine
administration also produces a large increase in dopamine release in the striatum of
schizophrenics (Lavalaye et al., 2001; Soares & Innis, 1999).
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Secondly, neonatal quinpirole treatments have been shown to produce deficits in auditory
sensorimotor gating using prepulse inhibition (PPI). PPI of the startle response refers to
attenuation in response to a strong stimulus (pulse) if this is preceded shortly by a weak nonstartling stimulus (prepulse). PPI provides a simple operational measure of sensorimotor gating
that is often disrupted in schizophrenia (Geyer, Krebs-Thomson, Braff, & Swerdlow, 2001;
Kumari & Sharma, 2002). Our laboratory has shown that adult rats that received neonatal
quinpirole treatment demonstrated PPI deficits as compared to controls using different prepulse
auditory intensities (73, 76, and 82 dB) and different intervals between the prepulse and pulse
(50, 100, and 150ms) (Maple, unpublished data).
Third, neonatal quinpirole treatments have been shown to produce long-term cognitive
impairment (Brown, Gass, & Kostrzewa, 2002; Brown, Thompson, Thompson, Thacker, Ward,
et al., 2004). It has been well-documented that severe cognitive impairments are present in
schizophrenia, and it has been suggested that cognitive impairment is a core feature of the
disorder (Adler et al., 1998; Adler, Freedman, Ross, Olincy, & Walso, 1999; Elvevag &
Goldberg, 2000). Cognitive deficits have also been hypothesized to be associated with
sensorimotor gating in schizophrenics (Geyer, Krebs-Thomson, Braff, & Swerdlow, 2001).
Fourth, our laboratory has very recently shown that chronic treatment with the atypical
antipsychotic olanzapine, or Zyprexa, given twice daily in adulthood alleviated cognitive deficits
produced by neonatal quinpirole treatment (Thacker et al., 2006). Importantly, this treatment also
alleviated the significant increase in yawning produced by rats neonatally treated with quinpirole
to control levels, essentially reversing the D2-priming effect. These data demonstrate that not
only is D2-priming likely primarily responsible for these behavioral effects, but that
antipsychotic treatments are effective in alleviating these effects. Additionally, in vitro analyses
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showed that significant decreases in nerve growth factor (NGF) in the hippocampus produced by
neonatal quinpirole were reversed by olanzapine in brain tissue that was not taken until after an
8-day olanzapine washout (Thacker et al.). However, expression of proteins was affected only in
the hippocampus and not in areas known to be important in cognitive functioning suggesting a
different mechanism for apparent alleviation of cognitive deficits in the Morris Water Maze task
(Brown, Perna, Maple, Wilson, & Miller, 2008).
Fifth, neonatal quinpirole treatments have been shown to alter overall brain function
through influences on other neurotransmitter systems, including the acetylcholinergic system,
(Brown et al., 2004; Brown, Perna, Schaefer, & Williams, 2006) and produce neurochemical
abnormalities in adulthood that are similar to observations made in human schizophrenics.
Results from this laboratory have shown that neonatal quinpirole treatment produced a 36%
decrease in choline acetyltransferase (ChAT) and a significant decrease in nerve growth factor
(NGF) expression in the hippocampus compared to saline controls in both early postweanling
and adult rats (Brown et al., 2004; Brown, Thompson, Click, Thacker, & Perna, 2005; Brown,
Perna, Maple, Wilson, & Miller, 2008). Research in non-medicated human schizophrenics have
demonstrated a decrease in overall NGF expression, which has been suggested to account for
neurodevelopmental abnormalities seen in schizophrenia (Aloe, Iannitelli, Angelucci, Bersani, &
Fiore, 2000; Parikh, Evans, Kahn, & Mahadik, 2003).
Finally, PCR analyses from our laboratory have shown a significant decrease in the
genetic expression of alpha7 nicotinic receptors in the hippocampus of D2-primed animals
(Brown et al., unpublished data). Reduced alpha7 expression is consistent with studies in human
schizophrenic patients that have shown a reduction in availability in the alpha7 nicotinic receptor
subunit gene (Leonard et al., 2002). Recently our lab has also shown decreases in RGS-9 protein
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expression (Maple, Perna, Parlaman, Stanwood, & Brown, 2007) in agreement with Seeman et
al. (2007) who have shown reductions in RGS9-2 mRNA expression in hippocampus tissue of
schizophrenics.
Therefore, it appears there are several similarities between the D2 receptor priming
model and schizophrenia, and this model may be valid for the study of this disorder. However,
further investigation of the effects of D2 priming on the serotinergic system, and the presence of
NMDA receptor hypofunction is required in order to further validate the neonatal quinpirole
model of schizophrenia.
Behavioral Sensitization
Behavioral sensitization is defined as an increase in behavioral response to repeated
presentations of a stimulus (Kelley & Rowan, 2004; Wise & Bozarth, 1987). Locomotor activity
is defined as horizontal movement and vertical rearing and is thought to result from activation of
mesolimbic dopamine projections from the ventral tegmentum to the nucleus accumbens during
psychomotor drug stimulation of the reward pathway, although other neurotransmitters are
undoubtedly involved as well (Clarke, Fu, Jakubovic, & Fibiger, 1988; Kalivas & Stewart, 1991;
Wise & Bozarth). Several drugs in the psychostimulant class, including amphetamine, cocaine,
and nicotine, have been shown to increase dopamine function and also produce locomotor
sensitization (Booze, Welch, Wood, Billings, Apple, & Mactutus, 1999; Chiang, Chen, & Chen,
2003; Kosowski & Liljequist, 2005; Kuczenski & Segal, 2001; Perna, in press; Segal &
Kuczenski, 1992; Tenn, Kapur, & Fletcher, 2005). Additionally, blockade of dopamine D1 and
D2 receptors through pretreatment with a D1 or D2 antagonist such as SCH 23390 or eticlopride
have been shown to block sensitization to psychostimulants (Schindler & Carmona, 2002).
Further, ablation of areas rich in dopaminergic cell bodies in the ventral tegmental area or
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dopaminergic terminals in the nucleus accumbens has also been shown to be effective in
blocking locomotor sensitization to psychostimulant drugs (Clarke et al., 1988). Thus, it appears
that the dopamine system plays a crucial role in locomotor sensitization to psychostimulants.
Anatomy of the Nucleus Accumbens
The primary brain pathway involved in drug addiction appears to be the
mesocorticolimbic pathway that originates from dopaminergic cell bodies in the ventral
tegmental area (VTA) of the midbrain and projects to the nucleus accumbens (NAcc), amygdala,
hippocampus, bed nucleus of the stria terminalis, and prefrontal cortex (Kumari & Postman,
2005; Vetulani, 2001).The nucleus accumbens has been shown to be the center of primary drug
reward in the brain and has been histologically defined in two parts: the core and the shell. Based
on histological analysis, the shell of the nucleus accumbens (AccSh) has been proposed to be an
extension of the amygdala, the emotional center of the brain that is thought to play an important
role in associative learning, particularly in situations involving rewarding and emotional
behaviors (Everitt, Morris, O’Brien, & Robbins, 1991; Meredith, Callen, & Scheuer, 2002). The
core sends projections to the substantia nigra and other areas associated with motor function such
as the putamen, caudate, globus pallidus, as well as the frontal cortex (Balfour, Wright, Benwell,
& Birrell, 2000; Mogenson & Yang, 1991). Increased dopamine transmission in the nucleus
accumbens shell during or immediately after drug administration is thought to account for the
reinforcing properties of drug use that facilitates addiction by consolidating associative learning
neural traces via D1 receptors (Di Chiara et al., 2004).
Role of the Nucleus Accumbens in Behavioral Sensitization
Increased locomotor activity after treatment with psychostimulants has been shown to
result from stimulation of dopaminergic neurons located in the nucleus accumbens core (Balfour
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et al., 2000; Imperato & Di Chiara as cited in Joseph, Datla, & Young, 2003; Pontieri, Tanda,
Orzi, & Di Chiara, 1996). According to the psychomotor theory of drug addiction proposed by
Wise and Bozarth (1987), locomotor activity can be used to predict the reinforcing effects and
addictive liability of drugs because both effects stem from a common mechanism involving the
nucleus accumbens that is also responsible for reinforcement associated with natural rewards
such as food and water. Natural rewards stimulate aversive centers through a feedback
mechanism in order to control reward-seeking behaviors. However, artificial chemical rewards
such as drugs of abuse stimulate the reward pathway but are not restrained by the controlling
feedback mechanism possibly producing addiction (Vetulani, 2001).
Drugs in the psychostimulant class, including nicotine, have been shown to have strong
associative properties that likely make them susceptible to addiction. For example, Pontieri et al.
(1996) used microdialysis, a technique for collecting neurotransmitter samples by perfusion of
artificial cerebrospinal fluid through a particular brain region using a specialized probe (Joseph
et al., 2003), to show dose-dependent increases in dopamine transmission in the nucleus
accumbens of rodents that were administered intravenous (i.v.) nicotine. Nicotine was
administered via an i.v. pulse in an attempt to approximate the pharmacokinetics of inhaled
nicotine from tobacco smoke. Pontieri et al. suggest that positive motivational states induced by
NAcc dopamine transmission may facilitate the association of contextual stimuli with the
psychostimulant effects of nicotine to acquire incentive properties through the process of
motivational learning.
Studies have shown an increase in dopamine release over subsequent administration of a
range of psychostimulants including amphetamine, cocaine, and methamphetamine (Akimoto,
Hamamura, Kazahaya, Akiyama, & Otsuki, 1990; Kalivas & Duffy, 1990; 1993; Wolf, White,
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Nassar, Brooderson, & Khansa, 1993). Behavioral sensitization is thought to result from this
increased dopamine release by neurons located in the VTA which creates dopamine overflow in
the nucleus accumbens core (Kalivas & Stewart, 1991). The NAcc core sends retroactive
projections to the midbrain motor centers, including substantia nigra, medial subthalamic
nucleus, and pedunculopotine motor region, resulting in increased locomotor activity (Pierce &
Kalivas, 1997).
Involvement of Dopamine Receptors in Nicotine Sensitization
It has been suggested that decreased inhibition of neurons controlled by presynaptic
dopamine D3 autoreceptors or increased postsynaptic D1 or D2 receptor sensitivity to dopamine
in the nucleus accumbens and striatum may play a role in the development of behavioral
sensitization and are associated with the processes underlying addiction (Balfour et al., 2000;
Chiang, Chen, & Chen, 2003; Le Foll, Diaz, & Sokoloff, 2003). Behavioral sensitization induced
by psychostimulant drugs such as nicotine may specifically reflect stimulation of dopamine
receptors within the core of the nucleus accumbens. However, results from a study by Le Foll,
Diaz, et al. (2003) showed increases in dopamine D3 receptor binding and mRNA expression in
the nucleus accumbens shell, but not core, after subchronic nicotine administration. In addition to
increased D3 receptor expression, studies have shown increases in dopamine transporters in
response to repeated nicotine administration (Harrod et al., 2004). Interestingly, studies to date
have failed to demonstrate changes in D1 or D2 receptor expression or sensitivity after repeated
nicotine administration (Harrod et al.; Le Foll, Diaz, et al.).
Dopamine D3 receptors have been shown to have greater occupancy for dopamine as
compared to D1 and D2 receptor subtypes (Richtand, Goldsmith, Nolan, & Berger, 2001). It has
been hypothesized that locomotor activity in rodents is mediated by the opposing actions of
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D1/D2 receptor activation and D3 receptor inhibition, and that rapid D3 receptor tolerance due to
increased affinity for dopamine and D3 receptor down-regulation after chronic psychostimulant
administration leads to observed increases in locomotor activity (Richtand, Goldsmith, Nolan, &
Berger, 2001; Richtand et al., 2000). D3 receptor antagonism has been shown to block
sensitization to amphetamine (Chiang, Chen, & Chen, 2003; Richtand et al., 2000) providing
support for this hypothesis. However, Filip, Papla, and Czepeil (2002) observed increases in the
expression of sensitization to cocaine after administration of the D3 receptor antagonist
nafadotride on the 10th day of drug administration. Another study showed that although
sensitization was observed, there were no significant differences in locomotor activity between
wildtype and D3-receptor knockout mice after repeated cocaine administration, suggesting that
D3-receptors do not play an important role in the expression of behavioral sensitization
(Betancur et al., 2001). These results may reflect species-specific neurochemical differences
between rats and mice or the development of a compensatory mechanism of D3 receptor
deficient mice to expression of sensitization. Therefore, involvement of the D3 receptor in
sensitization to different psychostimulants warrants further investigation in both species.
In a study by Le Foll, Schwartz, and Sokoloff (2003), D3 antagonism blocked the
conditioning effects of nicotine in rats that had nicotine repeatedly paired with a particular
environment. In another study utilizing the conditioned-place preference paradigm, Le Foll,
Sokoloff, Stark, and Goldberg (2005) showed that the selective D3 receptor antagonist ST 198
blocked the expression of nicotine-conditioned place preference without affecting locomotor
activity (Le Foll, Sokoloff, et al.). These results suggest that D3 receptors are selectively
involved in the associative effects of nicotine but may not play a role in the locomotor activating
effects of the drug (Le Foll, Schwartz, et al.; Le Foll, Sokoloff, et al.).
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The expression of D3 receptors and behavioral sensitization is thought to result from
changes in striatal and accumbal connectivity by repeated nicotine-administration triggered
release of brain-derived neurotrophic factor (BDNF) originating from cortico-striatal neurons
(Guillin et al., 2001; Le Foll, Diaz, et al., 2003). Guillin et al. (2001) have suggested that
repeated use of addictive drugs alters BDNF expression that subsequently influences dopamine
responsiveness in areas associated with environmental cues and context, such as the amygdala,
inducing drug-conditioned responses to contextual stimuli. In line with this hypothesis, LeFoll,
Diaz, et al. have also shown increased D3 receptor expression in the nucleus accumbens after
repeated conditioning of nicotine to an environmental context. Additional studies are needed to
determine the role of D3 receptors and their interaction with BDNF in drug addiction.
Involvement of Non-Dopaminergic Systems in Nicotine Sensitization
Balfour et al. (2000) suggest that projections in the shell of the nucleus accumbens
exhibit burst firing that is dependent upon N-methyl-D-aspartate (NMDA) receptor stimulation
by acute nicotine administration and is important for the initiation of behavioral sensitization.
However, chronic nicotine administration is required to stimulate burst firing in core projections.
Support for this hypothesis was demonstrated in several recent studies. Results from these
studies showed that NMDA receptor antagonists inhibited nucleus accumbens core dopamine
overflow in sensitized animals that were pretreated with nicotine. This group did not show
significant changes in the augmented locomotor response, suggesting a major role of post
synaptic dopamine receptors in the mediation of nicotine sensitization (Balfour, Birrell, Moran,
& Benwell, 1996; Birrell & Balfour, 1998; Shoaib, Benwell, Akbar, Stolerman, & Balfour, 1994;
Suemaru, Gomita, Furunu, & Araki, 1993).
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Nicotine Conditioned Hyperactivity
Behavioral sensitization can be achieved by using classical Pavlovian conditioning in
which a previously neutral stimulus, such as a particular environment, can acquire rewarding
properties through learned association. This occurs when a biologically rewarding stimulus, such
as nicotine, is temporally paired with an environmental context. Drug-associated conditioned
stimuli may also acquire the ability to elicit responses related to cravings, withdrawal, and drug
seeking behavior (Robinson, & Berridge, 1993; Siegel as cited in Bevins & Palmatier, 2003).
Bevins and Palmatier (2003) used a locomotor conditioning paradigm in which nicotine
was repeatedly administered and reliably paired with a locomotor arena every day for a total of 8
conditioning days. Contextual conditioning was followed by a drug-free trial in which animals
were given a saline injection and placed into the same locomotor arena that had been reliably
paired with nicotine. Results from this study showed significant increases in locomotor activity
in drug-context paired groups as compared to saline-context paired groups during the
postconditioning drug-free test, demonstrating the ability of an environmental context stimulus to
evoke nicotine-conditioned hyperactivity.
Nicotine conditioning to a particular context elicits locomotor hyperactivity that has been
hypothesized to result from positive reinforcement and, in theory, should also elicit increased
dopamine release. Although a significant increase in activity could result from other changes
produced by the drug, such as nicotine-induced nicotinic receptor upregulation, studies have
shown that dopamine may play an important role in nicotine conditioned hyperactivity. This
hypothesis is supported by the ability of D2 antagonists such as haloperidol to interfere with
conditioned stimulus control of sensitization (Kalivas & Stewart, 1991) and the ability of the
selective D3 antagonist SB-277011A to decrease nicotine-induced conditioned locomotor
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activity in rats (Pak et al., 2006). Bevins, Besheer, and Pickett (2001) have shown that
administration of the selective D1 antagonist SCH-23390 during the post nicotine drug-free trial
prevented the expression of a context-nicotine association. In a subsequent study, administration
of SCH-23390 during the conditioning phase did not affect the acquisition of a nicotineenvironment association suggesting a greater role of the D1 receptor in the expression, as
opposed to acquisition, of conditioned hyperactive behavior induced by nicotine (Bevins et al.).
Increases in nucleus accumbens dopamine release during drug-free testing would suggest
that schizophrenic patients may experience greater drug reinforcement when exposed to drugassociated cues than a normal individual due to further activity in an already hyperactive
dopaminergic system. Whether this increased locomotor activity is a product of an
overabundance of dopamine or reflects an increase in dopamine receptor sensitivity is yet to be
determined. Although dopamine appears to play an important role, the roles of other
neurotransmitter systems should also be evaluated.
Age Differences in the Effects of Nicotine on Behavior
Individuals who begin smoking at an early age have increased difficulty quitting as adults
(Jarvis, 2006). Faraday et al. (2003) suggest that this is due to differences in acute and long-term
effects of nicotine. Studies have shown that both male and female adolescent rats exposed to
nicotine demonstrated increased activity compared to saline control animals without drug
administration, whereas adult rats administered the same doses showed activity levels
comparable to saline-controls (Elliot, Faraday, Phillips, & Grunberg, 2005; Faraday, Elliot,
Phillips, & Grunberg, 2003). Adolescent rats also showed less sensitivity to nicotine’s initial
hypoactivity effects and adolescents that were initially exposed to nicotine demonstrated an
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overall increase in activity when reexposed to the drug as adults suggesting that early exposure
may alter adulthood response to nicotine (Elliot et al.; Faraday et al.).
In a recent study from our laboratory, dopamine D2-primed adolescent rats demonstrated
a more robust sensitization to nicotine as compared to adult rats (Perna, under review). Nicotine
sensitization was more robust in female subjects neonatally treated with saline as compared to
male subjects that received the same neonatal treatment. This is consistent with past findings by
Booze et al. (Booze et al., 1999; Harrod et al., 2004).
There are several possible mechanisms for age differences in reactions to nicotine. It has
been hypothesized that there may be different rates of metabolizing nicotine between adults and
adolescents (Faraday et al., 2003). However, there have been no significant differences in
nicotine metabolism mediated by CYP2A-6, an enzyme important for the clearance of nicotine,
in adolescents as compared to adults (Hukkanen, Jacob, & Benowitz, 2005). Lapin et al. (1987)
also failed to find sustained changes in metabolism after both acute and sustained nicotine
exposure. Additionally, age differences in nicotinic acetylcholine receptor distribution, density,
and affinity may also partly account for age differences in nicotine reactivity based on the
regulation of both decreased and increased activity by central nicotinic cholinergic systems (Di
Chiara as cited in Faraday et al., 2003; Stolerman, Garcha, & Mirza, 1995) Faraday et al. (2003)
suggest that a difference in nicotinic receptor subpopulations may exist with lower doses
activating the activity-decreasing subpopulation to a lesser extent in adolescents as compared to
adult rats.
Rate differences in receptor up-regulation and desensitization in response to drug
administration have been observed as adolescent D3 receptor levels at only 40% of adult levels
(Faraday et al. 2003; Shram, Funk, Li, & Le, 2006). Although speculative, this suggests
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schizophrenic patients who begin smoking during adolescence may have a more difficult time
quitting due to the decrease in negative responding to initial nicotine exposure possibly resulting
from decreased prevalence of the D3 receptors coupled with the potential cognitive deficit
alleviating capacity of nicotine. Differences in the rates of receptor up-regulation and
desensitization in response to nicotine administration may be especially important when
examining nicotine addiction in schizophrenia due to dopamine receptor dysfunction thought to
underlie the disorder.
Sex Differences in the Effects of Nicotine on Behavior
Although no sex differences in the initial response to nicotine have been reported, female
rats exhibit increased locomotor activity, greater sensitivity to lower doses, as well as an
increased number of the dopamine transporter (DAT) in both the shell and core of the NAcc after
chronic nicotine administration as compared to males (Booze et al., 1999; Elliot et al., 2005;
Faraday et al., 2003; Harrod et al., 2004; Kanyt, Stolerman, Chandler, Saigusa, & Pogun, 1999;
Perna, manuscript in preparation). Studies have shown increased levels of dopamine transporter
in female rats as compared to males resulting in increased synaptic availability of dopamine that
may account for, in part, for sex differences in locomotor activity (Booze et al., 1999; Harrod et
al., 2004). Studies have also shown that female rats do not exhibit hyperactive effects in the
absence of nicotine seen in males given the same doses (Elliot et al.; Faraday et al.). Sex
differences in dopamine D1 and D2 receptor sensitivity in response to both agonists and
antagonists after psychostimulant administration suggests that both receptors are important in the
locomotor activating effects observed in behavioral sensitization (Frantz & Van Hartesveldt,
1999; Schindler & Carmona, 2002). Differential expression of D3 receptors may also partially
explain sex differences in locomotor activity levels. It is possible that female rats exhibit higher
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activity levels due to a decrease in D3-regulated inhibition of activity. This hypothesis is
supported by autoradiography studies that have shown decreased numbers of D3 receptors in the
NAcc in female rats as compared to males after repeated intravenous nicotine administration
(Harrod et al., 2004).
Schindler and Carmona (2002) found a significant antagonistic effect of SCH 23390 and
increased locomotor activating effects of the dopamine uptake inhibitor GBR 12909 and the D1
agonist SKF 92958 in female rats as compared to males after cocaine administration. These
results suggest increased dopamine D1 receptor sensitivity in females. The authors also found
that male rats were more sensitive to the activity depressing effects of quinpirole suggesting that
D2 receptor function may possibly account for the lower activity of males as compared to female
rats after psychostimulant drug administration (Schindler & Carmona).
Studies from this laboratory (Brown, Thompson, Click, Best, Thacker, & Perna, 2005;
Brown, Perna, Schaefer, & Williams, 2006) have shown a three-fold increase in yawning, a D2mediated behavior, and deficits on a match-to-place Morris Water Task (MWT) in males
neonatally treated with quinpirole as compared to female rats suggesting further sex differences
in dopamine receptor sensitivity. Acute administration of the dopamine D2 antagonist eticlopride
before place-version MWT training to animals neonatally treated with saline produced deficits in
both male and female rats with males also showing deficits in a match-to-place MWT suggesting
a greater importance of the D2 receptor in cognitive performance in male versus female rats
(Brown, Thompson, et al.; Brown, Perna, et al.).
It is possible that sex differences observed in behavioral sensitization may be due to sex
differences in nicotine distribution, metabolism, (Kyerematen, Owens, Chattopadhyay,
deBethizy, & Vesell, 1988) and pharmokinetics as evidenced by higher nicotine arterial plasma
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levels in female rats chronically administered nicotine (Harrod, Booze, & Mactutus, 2007). It is
thought that sex-dependent differences observed in behavioral sensitization result in part from
modulation of striatal dopamine release by gonadal hormones (Booze et al., 1999; Dluzen &
Anderson, 1997; Harrod et al., 2004; Kanyt et al., 1999). Becker (1999) has shown that estrogen
down-regulates dopamine D2 autoreceptors and causes decreased firing of projections that
synapse on gamma-aminobutyric acid (GABA) –B receptor subtypes found on dopamine
receptor terminals resulting in enhanced striatal dopamine release. This enhancement of
dopamine release is thought to result in enhanced behavioral responses including locomotor
hyperactivity as a result of amphetamine stimulation, sensorimotor efficiency, and pacing during
sexual behavior (Becker, 1999). Dluzen and Anderson (1997) reported greater dopamine output
in tissue from castrated females treated with estrogen as compared to both male rats and female
castrated animals not treated with estrogen. The authors also showed a decrease in striatal
dopamine release in castrated males treated with estrogen demonstrating sex-dependent
bidirectional effects of estrogen (Dluzen & Anderson).
Studies have shown estrous cycle-dependent increases in amphetamine-induced release
of striatal dopamine as well as influences on sensorimotor functions and stereotypic behavior
(Becker & Cha, 1989; Becker, Snyder, Miller, Westgate, & Jenuwine, 1987). Estrous cycle
effects were not observed in nicotine self-administration behavior nor did estrogen appear to
have a significant effect on nicotine-induced locomotor hyperactivity in female rats (Donny et
al., 2000; Kuo et al., 1999). However, Franklin et al. (2004) have demonstrated significantly less
cue-induced cravings in women in the follicular phase of the estrous cycle as compared to
women in luteal phase or men suggesting an influence of sex hormones in response to nicotine or
at least in response to nicotine-associated cues. Further studies are needed to determine the
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extent, if any, that estrous cycle hormones affect behavioral responses to nicotine and nicotineassociated cues and whether these responses are altered by dopamine D2 receptor
supersensitivity.
Research Questions Addressed in this Thesis
The aim of this study was to examine the following:
1) Analyze the effects of the dopamine D2 and D3 receptor subtype antagonists
eticlopride and nafadotride, respectively, on the ability of a nicotine-conditioned context to
elicit locomotor activity in D2-primed and non-D2-primed adolescent rats. It was expected
that the D2 antagonist eticlopride (Bevins & Palmatier, 2002), but not the D3 antagonist
nafadotride, would block induction of nicotine sensitization. This prediction was guided by
Murray and Bevins (2007) who reported that relatively high doses of nafadotride are required to
inhibit locomotor activity and that this inhibition is probably the result of loss of D3 receptor
selectivity. However, based on the findings that nafadotride blocks the association of nicotine to
the locomotor arena, it was expected that nafadotride, but not eticlopride, would block nicotineconditioned hyperactivity during the drug-free trial (Bevins & Palmatier; Le Foll, Diaz, et al.,
2003; Le Foll, Schwartz, et al., 2003).
2) Compare nicotine-conditioned hyperactivity and locomotor sensitization in D2primed and non-D2- primed adolescent rats. A nicotine-conditioned environment was
predicted to elicit locomotor hyperactivity as supported by past evidence from Bevins and
Palmatier (2002) and that rats neonatally treated with quinpirole would show greater levels of
hyperactivity as compared to controls.
3) Analyze sex differences in nicotine-conditioned hyperactivity in both D2-primed
and non-D2-primed adolescent male and female rats. It was predicted that female rats would
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demonstrate higher activity levels as a result of sensitization to nicotine in the conditionedhyperactivity paradigm. This hypothesis was supported by past evidence that has shown females
demonstrate a more robust locomotor response to nicotine (Booze et al., 1999; Elliot et al., 2005;
Faraday et al., 2003; Harrod et al., 2004; Kanyt et al., 1999; Perna, in press). This increased
locomotor response would be further accentuated in D2-primed rats and greater activity will be
observed in females versus males.
4) Analyze sex differences in the effects of dopamine D2 and D3 antagonists
eticlopride and nafadotride, respectively, on nicotine-conditioned hyperactivity in both D2primed and non-D2-primed adolescent male and female rats. It was predicted that female rats
would show higher levels of locomotor activity as compared to males in response to
administration of dopamine D2 and D3 receptor antagonists. These hypotheses were based on
results indicating increased dopamine D1 receptor sensitivity to the activating effects of D1
receptor agonists and decreased sensitivity to activity depressing effects of D2 receptor agonists
in female rats as compared to males (Schindler & Carmona, 2002). Inhibition of the D2 receptor
would lead to a greater decrease in activity levels in male rats as compared to females. The
expected result was that females would exhibit higher activity levels in response to the dopamine
D3 receptor antagonist. This may possibly result from a decrease in D3-regulated inhibition of
activity based on findings that female rats had fewer D3 receptors in the NAcc after repeated
intravenous nicotine administration as compared to males (Harrod et al., 2004).
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CHAPTER 2
METHODS
Subjects
Ninety-eight offspring of Sprague-Dawley rats ordered from Harlan, Inc. (Indianapolis,
IN) were used in both experiments. The day of birth was counted as postnatal day zero (P0) and
pups were weaned from the dam at P22. Animals were housed in a climate-controlled vivarium
maintained on a 12 h light: 12 h dark cycle and food and water were available ad libitum. All
procedures used in this study were in accordance with and approved by the East Tennessee State
University Animal Care and Use Committee and the vivarium is fully accredited by the
Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC).
Drug dosage
Animals were administered of 10 mg/kg of quinpirole based on findings by Kostrzewa et
al. (1990) that this dose is sufficient to produce long-term priming of the dopamine D2 receptor.
Nicotine bitartrate (Sigma-Aldrich, St. Louis, MO) was diluted in saline to 0.5 mg/kg free base
(pH ~ 7.0). For Experiment 1, S-(-)-eticlopride hydrochloride (Sigma-Aldrich, St. Louis, MO)
was diluted in saline to 0.1 mg/kg based on findings by Palmatier and Bevins (2002) that this
dose is sufficient to impair locomotor activity in a nicotine conditioned hyperactivity paradigm.
For Experiment 2, L-nafadotride (Sigma-Aldrich, St. Louis, MO) was diluted in saline to 0.1
mg/kg based on findings by Murray and Bevins (2007) that this dose maintains specificity for the
dopamine D3 receptor subtype.
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Drug Treatment
Neonatal. On postnatal days 1 to 21 (P1-P21), animals were given a single daily
intraperitoneal (i.p.) injection of either quinpirole (10 mg/kg) or saline. Animals were randomly
assigned to treatment group in order to maintain relative sameness in group size. All animals
gained weight normally during drug treatment.
Adolescent. Animals were randomly assigned to treatment groups on P28. Animals were
drawn from 9 litters and were assigned to the following treatment group with the first drug
representing neonatal treatment, the second representing the administered antagonist (or Saline if
control group), and the third representing adolescent treatment: Saline-Saline-Saline (SSS),
Saline-Saline-Nicotine (SSN), Quinpirole-Saline-Saline (QSS), Quinpirole-Saline-Nicotine
(QSN) Saline-Eticlopride-Saline (SES); Saline-Eticlopride-Nicotine (SEN) QuinpiroleEticlopride-Saline (QES), Quinpirole-Eticlopride-Nicotine (QEN), Saline-Nafadotride-Saline
(SNS), Quinpirole-Nafadotride-Saline (QNS), Saline-Nafadotride-Nicotine (SNN), or
Quinpirole-Nafadotride-Nicotine (QNN). Animals in the SS, QS, SES, QES, SNS, and QNS
treatment groups served as the unpaired group (Bevins & Palmatier, 2003) which served as
controls for the context-nicotine paired groups. The rationale for this group is that these animals
received the same number of exposures to nicotine but did not have the drug paired within an
environmental context.
Apparatus
The two locomotor arenas were Plexiglas boxes painted black and measuring 72 cm on
all sides. The identical locomotor arenas served as the conditioning contexts. According to
classical conditioning, the locomotor arenas serve as the conditioned stimulus that elicits the
conditioned response of horizontal locomotor activity after being reliably and repeatedly paired
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with the unconditioned stimulus, nicotine. All activity was monitored by an automated
behavioral scanning system (Any Maze, Stoelting Co., Wood Dale, IL). A grid was
superimposed on the floor of the locomotor arena using the Any-Maze scanning system. Number
of lines crossed served as the dependent variable of horizontal activity. Two locomotor arenas
were used because the behavioral scanning system allowed for simultaneous data collection of
two subjects.
Behavioral testing procedure
Beginning on P29, animals were habituated to the locomotor arena for 3 consecutive
days. On each day of habituation, all animals were given an injection of saline and placed into
the locomotor arena 10 minutes later. Each habituation session lasted for 10 minutes. This was
done to allow animals to adapt to the locomotor apparatus and to the injection procedure.
Beginning on P32, animals were injected i.p. with either nicotine (0.5 mg/kg free base) or saline.
Animals were injected i.p. with either eticolopride (0.1 mg/kg), nafadotride (0.1 mg/kg), or
saline 10 minutes before the nicotine or saline injection. Ten minutes after the adolescent
treatment injection, the animals were placed into the locomotor arena for a 10-minute session.
This procedure was repeated every other day for 18 days resulting in 9 days of sensitization
testing.
Animals in the unpaired groups (SSS, QSS, SES, QES, SNS, and QNS) were
administered saline before being placed into the locomotor arena and nicotine in the home cages
2 h after conditioning to control for nicotine exposure. The unpaired groups are so named
because they receive the same number of exposures to nicotine; however, the drug is not
repeatedly or reliably paired with the conditioned context. For the conditioned hyperactivity test,
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all animals were given a saline injection and 10 minutes later were placed into the locomotor
arena for one 10-minute session and behavior was recorded.
Research Design and Data Analysis
An initial 2 (sex) x 2 (neonatal drug treatment) x 2 (antagonist) x 2 (adolescent) x 5
(repeated measure) five-way mixed factorial ANOVA was performed for both the eticlopride and
nafadotride treated groups. There was a significant sex main effect in each experiment.
Therefore, sex effects was analyzed separately using two 2 (neonatal) x 2 (antagonist) x 2
(adolescent) x 9 (day of testing) ANOVAs. The Newman-Keuls post hoc test was used to
analyze significant interactions.
Planned comparisons were used to analyze conditioned hyperactivity data collected
during the drug-free trial. These comparisons were made to answer the following specific
questions. Group SSS was compared to group SSN to determine whether nicotine elicited
conditioned-hyperactivity. Group SSN was compared to group SSN to determine the effect, if
any, of D2-priming on conditioned-hyperactivity. Group SEN was compared to group SSN to
examine the effect of eticlopride on conditioned hyperactivity. Finally, Group QEN was
compared group QSN to examine the effect of eticlopride on conditioned-hyperactivity in D2primed rats. The four planned group comparisons for conditioned hyperactivity were the same
for both males and female rats.
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CHAPTER 3
RESULTS
Sex Differences in Nicotine Sensitization for Rats Administered Eticlopride
Initial analyses. Although there were several significant main effects and interactions, the
initial analysis focused on analyzing sex differences and their interaction with drug treatment.
The initial 2 x 2 x 2 x 2 x 9-way ANOVA of sex, neonatal, antagonist (eticlopride or saline),
adolescent, and day of testing yielded a significant main effect of sex F(1,94) = 10.11, p<.002,
significant two-way interactions of Sex x Antagonist F(1,94) = 3.68, p<.05, Sex x Day of Testing
F(8,752) = 2.01, p<.04, a significant three-way interaction of Sex x Neonatal Drug Treatment x
Day of Testing F(8,752) = 2.30, p<.04 and Sex x Antagonist x Day of Testing F(8,752) 1.98,
p<.04.
Analysis of the significant sex main effect revealed that overall females were
significantly more active than males. Post hoc analysis of the significant interactions with the
Newman-Keuls test revealed that females administered saline in the absence of an antagonist
demonstrated significantly higher levels of activity than males administered saline, but females
and males were equivalent in their horizontal activity when administered eticlopride. Females
demonstrated higher levels of horizontal activity as compared to males on days 1-3 and 7-8. In
particular, females neonatally administered saline demonstrated higher levels of horizontal
activity as compared to males on days 4 and 8, and females administered saline demonstrated
significantly higher levels of horizontal activity a compared to males administered saline or
eticlopride on days 3-5 and 7-9. In summary, adolescent females demonstrated significantly
higher levels of horizontal activity than adolescent males, an effect that has been repeatedly
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observed in the research literature (Becker, 1999; Booze et al., 1999; Elliot et al., 2005; Faraday
et al., 2003; Harrod et al., 2004; Kanyt et al., 1999; Perna, 2006).
Horizontal Activity for Male Rats Administered Eticlopride. A 2 x 2 x 2 x 9 four-way
repeated measures ANOVA revealed a significant main effect of Antagonist F(1,47) = 50.99,
p<.001, significant two-way interactions of Antagonist x Adolescent Drug Treatment F(1,47) =
5.25, p<.027, Neonatal Drug Treatment x Day of Testing F(8,376) = 2.67, p<.007, Antagonist x
Day of Testing F(8,376) = 15.80, p<.001, Adolescent Drug Treatment x Day of Testing F(8,376)
= 7.72, p<.001, and significant three-way interactions of Neonatal Drug Treatment x Antagonist
x Day of Testing F(8,376) = 2.12, p<.033, and Adolescent Drug Treatment x Antagonist x Day
of Testing F(8,376) = 3.56, p<.001. Finally, a significant four-way interaction of Neonatal Drug
Treatment x Antagonist x Adolescent Drug Treatment x Day of Testing F(8,376) = 2.94, p<.02.
Most importantly, this interaction revealed that Male Group QSN demonstrated significantly
higher levels of horizontal activity than all other groups at days 7 through 9. Also, Male Group
SSN demonstrated significantly higher levels of horizontal activity than Group SSS at days 7
through 9 demonstrating sensitization in this group. Results of this analysis are shown in Figure
1.

Figure 1. Horizontal Activity for Males Administered Eticlopride
** indicates significance greater than all other groups (p < .05)
* indicates significance greater than control group SSS (p < .05)
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Figure 1. Horizontal Activity for Males Administered Eticlopride
** indicates significance greater than all other groups (p < .05)
* indicates significance greater than control group SSS (p < .05)
Horizontal Activity for Female Rats Administered Eticlopride. A 2 x 2 x 2 x 9 four-way
ANOVA revealed significant main effect of Antagonist F(1,49) = 126.67, p<.001, significant
two-way interactions of Antagonist x Adolescent Drug Treatment F(1,49) = 7.89, p<.007,
Neonatal Drug Treatment x Day of Testing F(8,392) = 2.73, p<.006, and Antagonist x Day of
Testing F(8,392) = 9.51, p<.001, two significant three-way interactions of Antagonist x
Adolescent Drug Treatment x Day of Testing F(8,392) = 3.69, p<.001, and Neonatal Drug
Treatment x Adolescent Drug Treatment x Day of Testing F(8,392) = 2.14, p<.03. Results of this
analysis are shown in Figure 2.
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First, the significant main effect of Antagonist demonstrated that eticlopride resulted in
lower levels of horizontal activity compared to all other groups. Post hoc analysis of the two-way
interactions revealed that animals administered nicotine or saline in adolescence demonstrated
significantly higher levels of horizontal activity compared to animals administered eticlopride or
saline. Females neonatally treated with saline demonstrated significantly higher levels of
horizontal activity at days 4 and 8. Females administered eticlopride demonstrated significantly
lower levels of horizontal activity from days 2 through 9.
Analysis of the three-way interaction of Antagonist x Adolescent Drug Treatment x Day
of Testing revealed that eticlopride effectively produced a significant decrease of horizontal
activity in females administered nicotine in adolescence as compared to animals administered
eticlopride plus saline during at days 3 and 6 through 9. Females neonatally administered saline
and given saline, as opposed to an antagonist, and nicotine in adolescence (Group SSN) had
significantly higher levels of horizontal activity at days 6 through 8. Interestingly, Group SSN
activity levels drop to control levels on day 9.
Finally, and most importantly, analysis of the significant three-way interaction of
Neonatal Drug Treatment x Adolescent Drug Treatment x Day of Testing revealed that females
administered saline neonatally and nicotine in adolescence demonstrated significantly higher
levels of horizontal activity at days 5 through 8 than all other groups. Additionally, females
administered quinpirole neonatally and nicotine in adolescence (Group QSN) were equivalent to
the control group of females administered saline neonatally during antagonism and in
adolescence (Group SSS). This effect replicates past work in adolescence that has shown that
D2-primed females administered nicotine appear to decrease horizontal activity due to increases
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in stereotypic behaviors, such as grooming, paw treading, and vacuous chewing movements late
in nicotine sensitization testing (Perna, 2006).

Figure 2. Horizontal Activity for Females Administered Eticlopride
** indicates significance greater than all other groups (p < .05)
* indicates significance greater than control group SSS (p < .05)
Sex Differences in Nicotine-Conditioned Hyperactivity for Rats Administered Eticlopride
Conditioned Hyperactivity for Male Rats Administered Eticlopride. There were four
planned group comparisons performed for conditioned hyperactivity in males: Groups SSN to
SSS, SSN to QSN, SEN to SSN, QEN to QSN, and SEN to SSN (see Figure 3). For the planned
group comparison of Group SSN to SSS, the independent t-test was not significant t(12) = .41,
p=.69, demonstrating that nicotine did not produce conditioned hyperactivity in adolescent
males. However, the planned comparison of Group SSN to QSN, was significant t(12) = 2.63,
p<.022, and Group QSN demonstrated a significant increase in horizontal activity as compared
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to Group SSN. The planned comparisons of SEN to SSS t(11) = .65, p=.53 and QEN to QSN
were also not significant t(12) = .92, p=.38.

Figure 3. Conditioned Hyperactivity for Males Administered Eticlopride
Conditioned Hyperactivity for Female Rats in Administered Eticlopride. The same four
planned group comparisons performed for males were also performed to examine conditioned
hyperactivity in females: Groups SSN to SSS, SSN to QSN, SEN to SSN, and QEN to QSN (see
Figure 4). For the planned group comparison of Group SSN to SSS, the independent t-test was
significant t(10) = 3.54, p<.006. Group SSN demonstrated a significant higher level of activity
on the drug free test than Group SSS. Likewise, Group SSN demonstrated significantly higher
levels of activity on the drug free test than Group QSN t(9) = 2.59, p<.03. The planned
comparison of Groups QEN and QSN was not statistically significant t(12) = .27, p=.78. The
planned comparisons of Group SSN to SEN revealed another significant effect t(12) = 2.27,
p<.04.
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Figure 4: Conditioned Hyperactivity for Females Administered Eticlopride
Sex Differences in Nicotine Sensitization for Rats Administered Nafadotride.
Initial Analyses. Similar to the analysis of rats administered eticlopride, there were
several significant main effects and interactions, but in this initial analysis we were primarily
interested in analyzing sex differences and their interaction with drug treatment. An initial nineway ANOVA with sex, neonatal, antagonist, adolescent, and day of testing (2 x 2 x 2 x 2 x 9)
yielded a significant main effect of sex F(1,77) = 7.43, p<.008, significant two-way interactions
of Sex x Antagonist F(1,94) = 3.68, p<.05, Sex x Day of Testing F(8,616) = 3.22, p<.001. Two
significant four-way interactions of Sex x Neonatal Drug Treatment x Antagonist x Day of
Testing F(8,616) = 3.0, p<.002 and Sex x Antagonist x Adolescent Drug Treatment x Day of
Testing.
The analyses of the first of these two higher order interactions revealed increased
horizontal activity in females administered saline as opposed to the D3 antagonist nafadotride at
days 4, 5, 8, and 9. There were no significant group differences in males. The analysis of the
latter of these two higher order interactions revealed that females neonatally treated with saline
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and administered nicotine during adolescent treatment demonstrated significantly higher levels
of horizontal activity than all other groups at days 5 through 9, and this effect was blocked by
nafadotride. Males neonatally administered saline and given nicotine in adolescence also
demonstrated a significant increase in horizontal activity at days 6, 8, and 9 as compared males
given saline at both time points. Again, this effect was blocked by nafadotride. Based on these
sex differences, males and females were analyzed separately.
Horizontal Activity for Male Rats Administered Nafadotride. A 2 x 2 x 2 x 9 four-way
ANOVA revealed no significant main effects. There significant two-way interactions of
Antagonist x Adolescent Drug Treatment F(1,45) = 7.37, p<.009, Antagonist x Day of Testing
F(8,360) = 3.19, p<.002, and Adolescent Drug Treatment x Day of Testing F(8,360) = 8.06,
p<.001. There was a significant three-way interaction of Neonatal Drug Treatment x Antagonist
x Day of Testing F(8,360) = 3.50, p<.001. Finally, there was a significant four-way interaction of
Neonatal Drug Treatment x Antagonist x Adolescent Drug Treatment x Day of Testing F(8,360)
= 2.01, p<.04. Results of this analysis are shown in Figure 5.
Post hoc analysis of the most complex interaction revealed that Group QSN had
significantly higher levels of horizontal activity on Days 7 through 9 compared to all other
groups. Group QNN demonstrated a significant increase in horizontal activity compared to
Group QSN on day 1 but was equivalent to controls, Group SSS, throughout testing. This result
demonstrates that nafadotride blocked locomotor sensitization to nicotine in D2-primed males
and also blocked the initial hypoactive response to nicotine. However, in non D2-primed males
nafadotride blocked locomotor sensitization to nicotine but, interestingly, produced an initial
hypoactive response in Group SNN as compared to Group SSN at day 1.
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Figure 5. Horizontal Activity for Males Administered Nafadotride
** indicates significance greater than all other groups (p < .05)
* indicates significance greater than control group SSS (p < .05)
$ indicates Group QNN was significantly greater than Group QSN on Day 1
Horizontal Activity for Female Rats Administered Nafadotride. A 2 x 2 x 2 x 9 four-way
ANOVA revealed a significant main effect of Antagonist F(1,39) = 7.94, p<.008, a significant
two-way interaction of Adolescent Drug Treatment x Day of Testing F(8,312) = 7.66, p<.001, a
significant three-way interactions of Antagonist x Adolescent Drug Treatment x Day of Testing
F(8,312) = 2.93, p<.003, and a significant four-way interaction of Neonatal Drug Treatment x
Antagonist x Adolescent Drug Treatment x Day of Testing F(8,312) = 2.14, p<.04. These results
are shown in Figure 6.
Most importantly, analysis of this four-way interaction revealed that Group SSN
demonstrated significantly higher levels of horizontal activity at days 5 through 8. Group QNN
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activity levels were equivalent to controls, Group SSS, at days 2 through 9. Groups QNN and
SNN, nafadotride groups that received nicotine, demonstrated significant hypoactivity on day 1
compared to control Group SSS. Interestingly, nafadotride blocked sensitization to nicotine; it
did not block the initial hypoactive response to nicotine on day 1. Female Group QSN
demonstrated significantly lower levels of horizontal activity as compared to Group SSN at days
5 through 8, presumably due to increased stereotypy in this group.

Figure 6. Horizontal Activity for Females Administered Nafadotride
** indicates significance greater than all other groups (p < .05)
* indicates significance greater than control group SSS (p < .05)
$ indicates Group QNN demonstrated significantly lower activity levels as compared to Group
SSS on Day 1
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Sex Differences in Nicotine-Conditioned Hyperactivity for Rats Administered Nafadotride
Conditioned-Hyperactivity for Male Rats Administered Nafadotride. Only two planned
comparisons were performed on conditioned hyperactivity: The comparison of Groups SNN to
SSN was made to examine if nafadotride blocked conditioned hyperactivity. The comparison of
Group QNN to QSN was performed to examine the effect of nafadotride on nicotine-conditioned
hyperactivity in D2-primed rats. The comparison of Groups SNN to SSN was not statistically
significant t(8) = .044, p=.96. In the comparison of QNN to QSN, the t-test was statistically
significant t(10) = 2.97, p<.01. Group QSN demonstrated significantly higher levels of
horizontal activity compared to Group QNN, demonstrating that nafadotride blocked nicotine
conditioned hyperactivity in adolescent males. These results are shown in Figure 7.

Figure 7. Conditioned Hyperactivity for Males Administered Nafadotride
Conditioned-Hyperactivity for Female Rats Administered Nafadotride. Similar to males,
only two planned comparisons were performed on conditioned hyperactivity. The first
comparison of QNN to QSN was designed to test whether D2-priming effects on nicotine
conditioned increases in locomotor activity were blocked by nafadotride. The second comparison
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of Groups SNN to SSN was designed to test whether nafadotride blocked nicotine conditioned
increases in locomotor activity in non D2-primed female adolescent rats. The planned
comparison of Group QNN to QSN was not significant t(12) = 1.34, p=.21. However, the
planned comparison of Groups SNN to SSN was significant t(9) = 3.09, p<.013. The results of
this analysis are shown in Figure 8.

Figure 8. Conditioned Hyperactivity for Females Administered Nafadotride
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CHAPTER 4
DISCUSSION
The results of the present study support previous findings that priming of the dopamine
D2 receptor results in enhanced behavioral sensitization to nicotine (Perna, 2006). In addition,
this study also demonstrated that antagonizing the D2 and D3 receptor subtype blocks this
sensitization suggesting differential roles of dopamine receptor subtypes in the induction of
nicotine sensitization. Antagonism of the D2 receptor blocked nicotine-conditioned hyperactivity
in female rats but not male rats. Nafadotride blocked nicotine-conditioned hyperactivity in D2primed male rats but not female rats. These results suggest sex-based differential roles of the D2
and D3 receptor subtypes on the association of nicotine with conditioned contextual cues.
Nicotine Sensitization
D2 priming blocked the initial hypoactive behavioral response typically observed after
administration of nicotine (Brown & Kolb, 2001). This result is in agreement with previous
findings that adolescent rats also showed less sensitivity to nicotine’s initial hypoactivity effects
(Elliot et al., 2005). Overall, D2 primed rats that received nicotine demonstrated a significant
increase in activity compared to other groups and reached the asymptote of locomotor response
to nicotine more rapidly as compared to controls. Results showed that in male rats D2 priming
enhanced sensitization to nicotine as compared to non D2-primed rats. In female D2-primed rats
administered nicotine demonstrated an increased hypoactive response after initial sensitization.
The quantitative decrease in horizontal activity after initial sensitization is hypothesized to result
from qualitatively observed increases in stereotypic behaviors such as sniffing, licking,
grooming, and rearing movements (Kelley, 2001; Lepekhina, & Tsitsurina, 2007). These
observations are in agreement with previous findings that female rats show increased periods of
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stereotypic behavior after administration of the psychostimulants amphetamine (Milesi-Halle,
McMillan, Laurenzana, Byrnes-Blake, & Ownes, 2007) and nicotine (Perna, 2006).
Another factor that may lead to increased stereotypic behavior in female rats is increased
dopamine D1 receptor sensitivity as compared to male rats (Schindler & Carmona, 2002).
Vezina and Stewart (1989) posit that the D1 receptor subtype plays a more important role in
locomotor sensitization to psychostimulants as compared to the D2 receptor subtype. However,
knockout studies have shown that D2 receptor mutants demonstrate more drastic reductions in
motor function as compared to D1 receptor mutants (Kobayashi et al., 2004). Reductions in
locomotor activity in D1 mutants are dependent upon the experimental protocol used suggesting
an important interrelationship between receptor subtypes in the control of motor activity
(Kobayashi et al.). However, differential findings of the importance of the D1 versus D2 receptor
in locomotor sensitization may reflect species specific differences in receptors.
Nicotine induced dopamine release in the nucleus accumbens, striatum, and to some
extent the frontal cortex, is modulated by presynaptic nicotinic acetylcholinergic receptors
(nAChRs) on dopaminergic terminals of neurons in the nucleus accumbens (Grady, Marks,
Wonnacott, & Collins, 1992; Marshall, Redfern, & Wonnacott, 1997). Nicotine also blocks the
inhibitory action of dopamine at the presynaptic D2 autoreceptor resulting in additional synaptic
availability of dopamine (Barik & Wonnacott, 2006). Increased receptor sensitivity combined
with increased neurotransmitter availability may, in part, account for the augmented behavioral
sensitization and sex differences in behavior observed in the present study.
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Antagonism of Dopamine Receptor Subtypes
D2 Receptor. In agreement with Bevins and Palmatier (2002), eticlopride blocked
induction of nicotine sensitization in male and female rats. Interestingly, eticlopride was more
effective at blocking sensitization to nicotine in D2-primed as compared to non D2-primed rats
which is presumably due to increased sensitivity of the D2 receptor as a result of neonatal
receptor priming (Kostrzewa, 1995), and eticlopride is binding more effectively to primed D2
receptors.
D3 Receptor. Inconsistent with findings by Murray and Bevins (2007), the D3 antagonist
nafadotride blocked sensitization in both D2-primed and non D2-primed male and female rats.
This result is also inconsistent with previous findings that nafadotride failed to block expression
of sensitization to the psychostimulant cocaine (Betancur et al., 2001; Filip, Papla, & Czepeil,
2002) but is consistent with past work with amphetamine (Chiang, Chen, & Chen, 2003;
Richtand et al., 2000). This may be a spurious result, but it may also be that the present results
reflect age differences in dopamine D3 receptor function, as all of these past studies have used
adults as subjects.
Adolescent D3 receptor levels have been shown to be at only 40% of adult levels during
the adolescent period (Faraday et al. 2003; Shram et al., 2006). Thus, it may be that these
receptors increase sensitivity due to their low number in the brain and play a larger role in
locomotor sensitization to nicotine in adolescence than in adulthood. On the other hand, it may
be that adolescent animals are more likely to demonstrate increases in stereotypic behaviors, as
observed in the present study in nicotine given to D2-primed females. Thus horizontal activity
may not be the most accurate behavioral measure for activation to psychostimulant drugs. One
important consistency however is that nafadotride fails to block sensitization to amphetamine
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(Chiang et al., 2003). Both amphetamine (Nowak, Brus, & Kostrzewa, 2001) and nicotine
(Benowitz, 2008) produce an increase in dopamine release and block the presynaptic dopamine
D2 receptor autoreceptor (Geldwert et al., 2006). Nicotine and amphetamine may have similar
actions at the synapse and these actions may be blocked by D3 antagonism. Further studies are
needed to examine sex differences in D3 receptor density and the possible effects of density on
the associative conditioning properties of nicotine.
Dopamine Receptor Density in Adolescence. Andersen and Teicher (2000) have shown
sex differences in dopamine receptor density over the periadolescent period, which has been
defined as occurring from approximately P28 to P60 (Smith, 2003), as compared to the adult
period. Dopamine D2 receptor density in the striatum of male rats increases 1.4 fold between
P25 and P40, whereas D2 receptor density in the striatum of female rats is increased by only
31% during this time. Male D2 receptor density sharply decreases by 55% by adulthood, whereas
females show little overproduction during the same developmental period. Interestingly, during
adulthood, there were no sex differences in the density of D1 and D2 receptors (Andersen &
Teicher).
The results of this study support previous findings that adolescent rats, particularly D2primed adolescents, demonstrated a more robust sensitization to nicotine as compared to adult
rats (Elliot et al., 2005; Perna, 2006), based on the increases in dopamine receptor density during
the adolescent period. Further, these increases in dopamine receptor density suggest that drugs
enhancing the dopaminergic system, such as addictive drugs, may have more prevalent effects
during this period. Certainly, the results shown here support this effect in males, as D2-primed
males demonstrated an enhanced sensitization to nicotine, suggesting increased behavioral
activation to nicotine.
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Alternative Mechanisms. Several studies have shown that multiple neurotransmitters
systems are affected by nicotine including the cholinergic (Brown et al, 2006; Quarta et al.,
2007), glutamatergic (Balfour et al., 1996; Birrell & Balfour, 1998; Domino, 2001; Shoaib et al.,
1994; Suemaru et al., 1993), and GABAergic systems (Carlsson, 2000). Blockade of nicotinic or
glutamatergic receptors has been shown to block sensitization to nicotine, suggesting that the
cholinergic or glutamatergic systems may also play a role in sensitization to nicotine.
Nicotinic receptors are located both pre- and postsynaptically, and the presynaptic
nicotinic receptor has been shown to be located on cholinergic, glutamatergic, serotinergic, as
well as dopaminergic neurons (McKay, Placzek, & Dani, 2007). This ubiquity of the nicotinic
receptor throughout the brain makes the action of nicotine difficult to understand. Certainly, had
an antagonist to another neurotransmitter system been used in the present study, it very well may
have blocked sensitization to nicotine, and it is realized that the mechanism underlying the
behavioral results observed in the present study may be mediated by several neurotransmitter
systems. Regardless, current evidence still supports increased dopamine release in the nucleus
accumbens via the direct agonist actions of nicotinic receptors located in the VTA (Di Chiara et
al., 2004; Perna, 2006; Shim et al., 2001; Shoaib et al., 2004).
Nicotine-Conditioned Hyperactivity
Results suggest that D2 priming enhanced conditioned hyperactivity to nicotine in males,
and this effect was not blocked by the D2 antagonist eticlopride. Further, non D2-primed males
administered nicotine did not demonstrate conditioned hyperactivity. Results showed that
eticlopride, a dopamine D2 antagonist, blocked conditioned hyperactivity in females but not in
males, suggesting that the D2 receptor plays a role in the association of nicotine with a
conditioned context, at least in females. This is somewhat consistent with past research.
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Schindler and Carmona (2002) have shown that adult female rats demonstrate an increase in
locomotor activation to acute quinpirole. The result that females administered eticlopride failed
to demonstrate nicotine conditioned hyperactivity further supports results showing there are sex
differences in D2 receptor function, especially in adolescence.
The results using the dopamine D3 antagonist nafadotride were more complex. First,
nafadotride blocked conditioned hyperactivity in non D2-primed females. This result, taken with
the findings with the D2 antagonist eticlopride, suggests that both the D2 and D3 receptor play a
role in the conditioned effects of nicotine in females. Further, because D2-primed females did
not demonstrate conditioned hyperactivity to nicotine, it does not appear that priming of the D2
receptor in females affects associative effects of nicotine as it relates to behavioral activation.
Nafadotride was effective in blocking conditioned hyperactivity in D2-primed males, but
because non D2-primed males did not demonstrate nicotine conditioned hyperactivity, it did not
produce any effects in this group. Thus, the D3 receptor may play a more important role in
expression of behavioral activation to nicotine in males as compared to females; however, there
is a reasonable alternative explanation.
To produce priming of the dopamine D2 receptor, ontogenetic quinpirole was
administered. Quinpirole is a dopamine D2/D3 agonist, thus, both D2 and D3 receptors may be
primed. Further, work by Collins et al. (2005) has shown that the D3 receptor is more important
in yawning behavior as compared to the D2. All of this taken together suggests that the D3
receptor may also be primed in these animals and may be playing a more important role in
nicotine association in males as compared to the D2 receptor. Increased sensitivity of the D3
receptor, which has been shown to play an important role in the association of nicotine with a
conditioned context (Le Foll et al., 2005), may have resulted in increased behavioral response to
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the conditioned context during the drug-free trial. This is especially interesting considering the
importance of the dopamine system in addiction to nicotine, and sex differences that have been
shown in not only schizophrenics (Leung & Chue, 2000) but in the normal population (Bigos et
al., 2008).
Initially, the finding that non-D2-primed females exhibited a significantly higher
conditioned hyperactivity response as compared to D2-primed females and controls is surprising.
However, previous studies by Harrod et al. (2004) have shown decreased numbers of D3
receptors in the NAcc in female rats as compared to males after repeated intravenous nicotine
administration. The reduction in supersensitized D3 receptors in the accumbens shell of D2primed female rats as a result of chronic nicotine administration may partially account for this
finding.
The importance of the D3 receptor in association of drugs of abuse with contextual
stimuli may be due to the increased number of receptors in the accumbens shell as compared to
the core (Stanwood, McElligot, Lu, & McGonigle, 1997). As previously mentioned, the shell of
the nucleus accumbens (AccSh) has been proposed as a histological extension of the amygdala,
the emotional center of the brain that is thought to play an important role in associative learning
in rewarding situations (Everitt, Morris, O’Brien, & Robbins, 1991; Meredith, Callen, &
Scheuer, 2002). Therefore, it is not surprising that administration of the D3 antagonist more
effectively blocked nicotine-conditioned hyperactivity as compared to the D2 antagonist
eticlopride.
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Clinical Relevance
The findings of the current studies present several considerations for the treatment of
nicotine addiction, particularly in the schizophrenic population. The apparent importance of the
D2 receptor in nicotine sensitization suggests that treatments targeting the D2 receptor may be
useful for simultaneous cessation of smoking and treatment of the positive symptoms of
schizophrenia as it appears. The increased sensitivity of D2-primed rats to nicotine exposure
provides additional support for D2-priming as an animal model of schizophrenia. This result is
consistent with human schizophrenia literature focused on nicotine addiction in this group (SalinPascual, Alcocer-Castillejos, & Alejo-Galarza, 2003). Bigos et al. (2008) have recently shown
that smoking impacts the metabolism of and may therefore reduce the effectiveness of
olanzapine in the treatment of schizophrenia. Therefore, drug interactions must always be
considered when developing new treatments.
As noted by Le Foll et al. (2007), the D3 receptor represents another potential target for
the treatment of nicotine addiction. Findings from this study support the role of D3 receptors in
the association of nicotine to conditioned stimuli as evidenced by the blockade of nicotineconditioned hyperactivity during the drug-free trial. Targeting the D3 receptor may be especially
beneficial for male schizophrenic patients indicated by the result that D2-primed male rats
showed the highest levels of conditioned hyperactivity. The D3 receptor provides a potential
target for treatment of cravings associated with stimuli associated with smoking. Perhaps
development of a pharmacological agent that antagonizes both the D2 and D3 receptor will aid in
the reduction of nicotine addiction by relieving both the physical and associative addiction to
nicotine that smokers suffer.
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Conclusion
The aim of this investigation was to determine the effect of a nicotine-conditioned
context on locomotor hyperactivity in an animal model of D2-priming, and whether conditioned
hyperactivity could be blocked by the D2 antagonist eticlopride or the D3 antagonist nafadotride.
The results of this study demonstrate that the D2 and D3 dopamine receptor subtypes are
important in both the locomotor activating effects of nicotine and also the association of nicotine
with conditioned stimuli, particularly environmental cues. More specifically, results
demonstrated that a nicotine-conditioned context can elicit hyperactivity and that hyperactivity is
blocked by both D2 and D3 receptor antagonism in female rats and D3 receptor antagonism in
male rats. These results also demonstrate differences in locomotor activity levels of D2-primed
and non D2-primed rats suggesting that nicotine will also have different effects in schizophrenic
patients as compared to the general population.
These results support previous findings that demonstrate the existence of sex differences
in locomotor sensitization and hyperactivity that may result from differences in receptor
sensitivity or density (Harrod et al., 2004; Le Foll, Diaz, et al., 2003; Schindler & Carmona,
2002) during different developmental periods. Sex differences in receptor subtype density during
adolescence, receptor sensitivity throughout development, and the introduction of differential
hormone levels at sexual maturity are all factors that impact nicotine’s effects on behavior. This
study highlights the need for additional research in sex differences, age differences, and the
importance of these two factors in the development of new treatments for nicotine addiction not
only in schizophrenia, but also the general population.
It is also important to point out that all antipsychotics used to treat schizophrenia block
the dopamine D2 receptor with some affinity. The results of this study demonstrate that the D2
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and D3 receptor are involved in both the physiological and psychological aspects of nicotine
addiction. The applications of these findings are very important relative to the interaction of
pharmacological treatment and typical nicotine abuse in the schizophrenic population. Therapies
should focus not only on pharmacologically treating the psychological addiction to nicotine but
also the psychological addiction triggered by environmental cues.
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adolescent D2-primed rats: Effects of exposure on initial nicotine
activity in adulthood. Poster session presented at the annual
meeting for the Society for Neuroscience, San Diego, CA.
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(2008, March). Dose-response analysis of methylphenidate
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for the Society for Neuroscience, Washington, DC.
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